Germany has accounted for a 3.9% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 6.4% share, according to GlobalData .

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Germany

Industry sponsored trials held an 88.8% share of all the clinical trials in Germany in 2020, when compared with the ten-year average of 87.8%. Non-industry sponsored trials accounted for an 11.2% share in 2020 as against the average of 12.2% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in Germany

Oncology was the leading therapy area for industry sponsored clinical trials in Germany in 2020 with a 32.7% share, as against a five-year average of 30.2% and a ten-year average of 28.2%.

Infectious Disease held an 11.0% share in 2020, over a five-year average of 6.3% and a ten-year average of 8.1%.

Central Nervous System held a 9.5% share in 2020, compared to a five-year average of 11.6% and a ten-year average of 12.1%. Respiratory held an 8.8% share in 2020, as against a five-year average of 7.6% and a ten-year average of 8.0%.

Immunology held an 8.3% share, over a five-year average of 9.6% and a ten-year average of 9.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in Germany

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in Germany in 2020 with a 26.8% share, as against a five-year average of 7.3% and a ten-year average of 7.8%.

Oncology held a 21.6% share in 2020, over a five-year average of 21.5% and a ten-year average of 22.3%.

Central Nervous System held a 15.5% share in 2020, compared to a five-year average of 25.6% and a ten-year average of 24.3%. Respiratory held a 10.3% share in 2020, as against a five-year average of 4.1% and a ten-year average of 4.0%.

Cardiovascular held a 9.3% share, over a five-year average of 13.5% and a ten-year average of 13.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase III trials lead industry sponsored clinical trials in Germany in 2020

Phase III trials held a 39.3% share of industry sponsored clinical trials in Germany in 2020, over a five-year average of 38.8% and a ten-year average of 38.8%.

Phase II trials held a 38.9% share in 2020, as against a five-year average of 36.0% and a ten-year average of 34.5%. Phase I trials held a 13.6% share in 2020, compared to a five-year average of 13.9% and a ten-year average of 13.7%.

Phase IV trials held an 8.2% share in 2020, over a five-year average of 11.3% and a ten-year average of 12.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in Germany in 2020

Phase II trials held a 51.5% share of non-industry sponsored clinical trials in Germany in 2020, over a five-year average of 55.7% and a ten-year average of 50.2%.

Phase III trials held a 21.6% share in 2020, as against a five-year average of 13.9% and a ten-year average of 16.3%. Phase I trials held a 13.4% share, compared to a five-year average of 7.2% and a ten-year average of 8.9%.

Phase IV held a 13.4% share in 2020, over a five-year average of 23.2% and a ten-year average of 24.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.